patpatpat, 28. Oktober 2013 um 15:04:00 MEZ Abt. best case - heute: Uni Basel erhält 35 Mio$ plus Soeben haben wir die provisorischen Unterlagen des Börsenganges von Glycomimetics erhalten: GlycoMimetics eRed
(application/pdf, 1.434 KB)
. 164 Seiten Kleingedrucktes für Fans! Die Uni Basel hatte im Jahresbericht 2011 geschrieben: In den Unterlagen zum Börsengang erfahren wir aber jetzt Folgendes auf S. 48: Über die Zusammenarbeit mit Pfizer schreibt Glycomimetics auf S. 47: In October 2011, we entered into the license agreement with Pfizer under which we granted Pfizer an exclusive worldwide license to develop and commercialize products containing GMI-1070 for all fields and uses. The license also covers specified back-up compounds along with modifications of and improvements to GMI-1070 that meet defined chemical properties. Pfizer is required to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for and commercialize GMI-1070 for sickle cell disease in the United States. Under the terms of the agreement, we received a $22.5 million upfront payment. We are also eligible to earn potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications, up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications, and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties for each licensed product, with percentages ranging from the low double digits to the low teens, based on net sales worldwide, subject to reductions in specified circumstances. The first potential milestone payment that we might be entitled to receive under the Pfizer agreement is $35.0 million upon the initiation of dosing of the first patient in a Phase 3 trial of GMI-1070 by Pfizer. In some specified circumstances, if Pfizer has not initiated dosing by April 2014, Pfizer is obligated to make an advance payment to us of $15.0 million against the first milestone payment. Pfizer has advised us through the joint steering committee established under the agreement that they intend to begin enrolling patients for a Phase 3 trial of GMI-1070 in mid-2014, pending approval through Pfizer’s governance process. Pfizer has also informed us through the joint steering committee that activities necessary to support the initiation of a Phase 3 trial in mid-2014 are currently underway pending approval through Pfizer’s governance process. The steps that Pfizer has taken and is taking to prepare for a Phase 3 trial include manufacturing of the drug substance to be used in the Phase 3 trial, completion of toxicology studies that would support a Phase 3 trial and an NDA, engagement with regulatory authorities in the United States and overseas to discuss plans for the conduct of a Phase 3 trial, planning and preparation for a so-called TQTc clinical trial to evaluate cardiac safety that would support a Phase 3 trial, contracting with a CRO to provide services in the conduct of a Phase 3 trial and convening clinical investigators in the United States and overseas to discuss plans for a Phase 3 trial. Although Pfizer has taken and is taking a number of steps to prepare for Phase 3 initiation in mid-2014, there can be no assurance that Pfizer will proceed on that schedule, or at all. There also can be no assurance that, if Pfizer does not initiate dosing by April 2014, the conditions to its obligation to make the $35.0 million milestone payment or the $15.0 million advance will be satisfied.Zusammengezählt ergibt das - Irrtum vorbehalten: 355 Millionen Dollar stehen Glycomimetics noch zu im Erfolgsfall. Und später weitere Lizenzgebühren aus den Verkäufen von Pfizer. Das heisst weiter: Im besten Fall erhält die Uni Basel von Glycomimetics rund 35 Millionen Dollar Erfolgsbeteiligung plus später 10% der Lizenzzahlungen von Pfizer. Warum hat eigentlich die Uni Basel so ein Tamtam um die Zahlen gemacht? Das bleibt wohl weiterhin ihr Geheimnis… Read more infamous news! |
infamous for 8183 Days
Sperrfrist: 02.09.24, 09:53
Motto: "Journalism is printing what someone else does not want printed. Everything else is public relations." @infamyblog folgen Youre not logged in ... Login
... infamy home ... such! ... topics ... ... Home
... Tags
... Galleries
... antville home
... disclaimer
Abt. Keintunnel
Nicht
vergessen, die Auto-Nerds wollen Milliarden in den Autobahnbau verlochen. Das ist sowas...
by bagger (02.09.24, 09:53)
Abt. Witz des Tages "Es
soll sogar prominente Klimakleber geben, die Flugreisen nicht grundsätzlich ablehnen,...
by bagger (15.06.24, 18:30)
Abt. Wohnschutz schützen Wenn die
Investoren husten, haben Basels Bürgerliche Grippe In einem beispiellosen Akt...
by bagger (15.06.24, 10:21)
Abt. Leckerschlecker The DEA
Northeast Laboratory (New York, New York) recently received a submission of...
by fuzzy (26.02.24, 12:06)
Abt. Wo-Wo-Wochenschau!
Männiglich fragte sich, was eigentlich Fonzis Leihkampffisch so macht. Die Antwort (oben) entnehmen...
by fuzzy (26.02.24, 12:04)
Abt. infamous Shooting
Foto: Fonzi Tromboni Gestern abend war grosses Fotoshooting im Studio zu Sankt...
by fuzzy (26.02.24, 11:55)
infamy loves: 468 Mobile News 78s Crocodile Bikes Lacoba Guayaberas Landistuhl by Westermann Medienwoche Qin's Asian Antiques Starfrosch Zeitnah - Kulturmagazin seit 2012
infamily of Blogs: Radio 2.0 sesam watch Bagger, Laster & Co. Wochenschau Tromboni-Blog Handspielers Journal Voltaplatz Fred berichtet infamy @ twitter fröhliche Wissenschaft Leo & Till infamyleaks @ privacybox
Friendly Blogs: Arlesheim Reloaded Bö CH Internet Szene contextlink Dometown Arlesheim fehler.li Fetch On Fire Journalistenschredder Medienspiegel Medienwoche Sennhausers Filmblog Strafprozess |